<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pimecrolimus: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pimecrolimus: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pimecrolimus: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10974" href="/d/html/10974.html" rel="external">see "Pimecrolimus: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12706" href="/d/html/12706.html" rel="external">see "Pimecrolimus: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709211"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term safety of topical calcineurin inhibitors has not been established. Continuous long-term use of topical calcineurin inhibitors, including pimecrolimus, in any age group should be avoided, and application limited to areas of involvement with atopic dermatitis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Although a causal relationship has not been established, rare cases of malignancy (eg, skin malignancy, lymphoma) have been reported in patients treated with topical calcineurin inhibitors including pimecrolimus.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatrics:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Pimecrolimus is not indicated for use in children younger than 2 years.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F209930"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Elidel</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867930"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Elidel</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F209947"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Calcineurin Inhibitor;</li>
<li>
                        Immunosuppressant Agent;</li>
<li>
                        Topical Skin Product</li></ul></div>
<div class="block doa drugH1Div" id="F209933"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67e9e2b-6dad-418d-9ecc-84f4de0f5978">Atopic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis (mild to moderate):</b>
<b>Topical:</b> Apply thin layer to affected area twice daily. <b>Note:</b> Limit application to involved areas. Discontinue use when symptoms have resolved; re-evaluate if symptoms persist &gt;6 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a52f4bde-14a6-4ccf-a8aa-ca6c993b1483">Oral lichen planus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral lichen planus (off-label use):</b>
<b>Topical:</b> Apply twice daily for 1 month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17438179','lexi-content-ref-15857105','lexi-content-ref-18647310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17438179','lexi-content-ref-15857105','lexi-content-ref-18647310'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c51dc6e-ca0a-48cc-bfad-6cb5d9403c14">Psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriasis (intertriginous and facial) (off-label use):</b>
<b>Topical:</b> Apply twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32738429','lexi-content-ref-15523351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32738429','lexi-content-ref-15523351'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="256e3f8c-30ca-421e-8e2c-dd72c6311be9">Vitiligo</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitiligo (off-label use): Topical:</b> Apply twice daily for 6 months. Treatment beyond 12 months may be useful; long-term safety has not been established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18608735','lexi-content-ref-19651562','lexi-content-ref-22860621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18608735','lexi-content-ref-19651562','lexi-content-ref-22860621'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block doe drugH1Div" id="F209934"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F209940"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12706" href="/d/html/12706.html" rel="external">see "Pimecrolimus: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67e9e2b-6dad-418d-9ecc-84f4de0f5978">Atopic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Atopic dermatitis (mild-moderate):</b> Children ≥2 years and Adolescents: Topical: Apply a thin layer to affected area twice daily; limit application to affected areas only; discontinue therapy when symptoms have resolved; re-evaluate patient if symptoms persist &gt;6 weeks.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F209910"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Headache (children and adolescents 11% to 25%; adults 7%), fever (children and adolescents 13%; adults 1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infection: Influenza (3% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Local: Local burning (adults 26%; children and adolescents 2% to 8%; tends to resolve/improve as lesions resolve), application site reaction (adults 15%; children and adolescents 2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Respiratory: Nasopharyngitis (infants, children, and adolescents 10% to 27%; adults 8%), upper respiratory tract infection (children and adolescents 14% to 19%; adults 4%), cough (children and adolescents 9% to 16%; adults 2%), bronchitis (children and adolescents ≤11%; adults ≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Folliculitis (adults 6%; children and adolescents 1%), skin infection (5% to 6%), impetigo (4%), warts (children and adolescents ≤3%), acne vulgaris (≤2%), herpes simplex dermatitis (≤2%), molluscum contagiosum (children and adolescents ≤2%), urticaria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Diarrhea (children and adolescents 1% to 8%; adults ≤2%), gastroenteritis (children and adolescents ≤7%; adults 2%), vomiting (1% to 4%), constipation (children and adolescents ≤4%), abdominal pain (≤3%), toothache (≤3%), nausea (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Genitourinary: Dysmenorrhea (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hypersensitivity: Hypersensitivity (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infection: Viral infection (children and adolescents ≤7%), herpes simplex infection (≤4%), bacterial infection (1% to 2%), staphylococcal infection (1% to 2%), varicella (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Local: Local irritation (adults ≤6%; children and adolescents ≤1%), local pruritus (1% to 6%), localized erythema (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuromuscular &amp; skeletal: Arthralgia (≤2%), back pain (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ocular: Conjunctivitis (≤2% to 3%), eye infection (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Otic: Otic infection (1% to 6%), otitis media (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Respiratory: Sore throat (4% to 8%), pharyngitis (children and adolescents 1% to 8%; adults 1%), tonsillitis (children and adolescents ≤6%; adults &lt;1%), asthma (3% to 4%), asthma aggravated (children and adolescents ≤4%), streptococcal pharyngitis (children and adolescents 3%), nasal congestion (1% to 3%), sinusitis (1% to 3%), epistaxis (≤3%), dyspnea (≤2%), flu-like symptoms (≤2%), pneumonia (≤2%), rhinitis (≤2%), rhinorrhea (children and adolescents ≤2%), viral upper respiratory tract infection (≤2%), wheezing (children and adolescents ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Miscellaneous: Laceration (children and adolescents ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, eczema (herpeticum), eye irritation (following application near eyes), facial edema, flushing (ethanol-associated), lymphadenopathy, malignant  neoplasm (basal cell carcinoma, squamous cell carcinoma, malignant melanoma, malignant lymphoma), skin discoloration</p></div>
<div class="block coi drugH1Div" id="F209922"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to pimecrolimus or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F209908"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Infection: Patients with atopic dermatitis are predisposed to skin infections; therapy has been associated with an increased risk of developing eczema herpeticum, varicella zoster, and herpes simplex. Do not apply to areas of active bacterial or viral infection; local infections at the treatment site should be resolved prior to therapy.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Local symptoms: May cause local symptoms (eg, burning, pruritus, soreness, stinging) during first few days of treatment; usually self-resolving as atopic dermatitis lesions heal.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Lymphadenopathy: May be associated with development of lymphadenopathy; possible infectious causes should be investigated. Discontinue use in patients with unknown cause of lymphadenopathy or acute infectious mononucleosis. </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Malignancy: <b>[US Boxed Warning]: Topical calcineurin inhibitors (including pimecrolimus) have been associated with rare cases of lymphoma and skin malignancy; </b> avoid use on malignant or premalignant skin conditions (eg, cutaneous T-cell lymphoma).</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Skin papilloma: Skin papilloma (warts) have been observed with use; discontinue use if there is worsening of skin papillomas or they do not respond to conventional treatment. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Atopic dermatitis: Diagnosis should be reconfirmed if sign/symptoms do not improve within 6 weeks of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Erythroderma: Safety not established in patients with generalized erythroderma.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Skin diseases which may increase systemic absorption: Not recommended for use in patients with Netherton's syndrome or skin conditions which may increase the potential for systemic absorption. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Immunocompromised patients: Should not be used in immunocompromised patients, including patients on concomitant systemic immunosuppressive therapy.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Pediatric: <b>[US Boxed Warning]: Use of pimecrolimus in children &lt;2 years of age is not recommended,</b> particularly since the effect on immune system development is unknown.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Appropriate use: <b>[US Boxed Warning]:  Continuous long-term use of calcineurin inhibitors (including pimecrolimus) should be avoided and application of cream should be limited to areas of involvement with atopic dermatitis.</b> Safety of intermittent use for &gt;1 year has not been established.  </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Sun exposure: Avoid artificial or natural sunlight exposure, even when pimecrolimus is not on the skin.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878592"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Clinical trial experience of 436 infants and children &lt;2 years reported a higher incidence of detectable serum concentrations (possibly related to larger BSA:mass ratio) and infection (upper respiratory) or infection-related symptoms than comparative placebo (vehicle) group and older pediatric patients. Pimecrolimus long-term effects on the developing immune system are unknown.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F209917"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elidel: 1% (30 g, 60 g, 100 g) [contains benzyl alcohol, cetyl alcohol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (30 g, 60 g, 100 g)</p></div>
<div class="block geq drugH1Div" id="F209905"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F209923"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Elidel External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per gram): $11.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Pimecrolimus External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per gram): $10.15 - $10.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867931"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elidel: 1% (15 g, 30 g, 60 g, 100 g) [contains benzyl alcohol, cetyl alcohol, propylene glycol]</p></div>
<div class="block adm drugH1Div" id="F209919"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b> Apply a thin layer to affected skin. Limit application to areas of involvement. Do not use with occlusive dressings. Burning at the application site is most common in first few days but improves over time. Discontinue use when symptoms have resolved; re-evaluate if symptoms persist &gt;6 weeks. Moisturizers may be applied after use of pimecrolimus cream. Wash hands before and after use.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral lichen planus (off-label use): Apply to affected oral mucosa, cover with a thin layer of gauze to delay dilution with saliva (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18647310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18647310'])">Ref</a></span>). Eating, drinking, or chewing gum was not allowed for 30 minutes after application (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17438179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17438179'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613589"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;">Topical: Apply a thin layer of cream over affected area; limit application to areas of involvement; do not use with occlusive dressings. Burning at the application sites is common in the first few days of treatment and improves as atopic dermatitis improves. Discontinue use when symptoms have resolved. Avoid contact with eyes, nose, mouth and with cut, scraped, or infected skin areas. Wash hands with soap and water prior to and after cream application. If applying cream after a bath or shower, make sure skin is dry. Moisturizers may be applied after use of pimecrolimus cream.</p></div>
<div class="block hazard drugH1Div" id="F49133445"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Pimecrolimus may cause carcinogenicity and has a structural or toxicity profile similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protections is recommended (NIOSH 2016).</p></div>
<div class="block meg drugH1Div" id="F7874783"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F73430%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPPc2JBEoPlCUz2cgzk7L5DXiJfN1DSyzNXfU6tb0hi2yrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=10162" target="_blank">https://www.fda.gov/media/73430/download</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F209918"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Atopic dermatitis:</b> Second-line therapy for short-term and noncontinuous long-term treatment of mild to moderate atopic dermatitis in nonimmunocompromised patients 2 years and older who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.</p></div>
<div class="block off-label drugH1Div" id="F25470538"><span class="drugH1">Use: Off-Label: Adult</span><p>Oral lichen planus; Psoriasis (intertriginous and facial); Rosacea; Vitiligo</p></div>
<div class="block mst drugH1Div" id="F7898347"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pimecrolimus may be confused with tacrolimus</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F209941"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F209912"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the dermatologic adverse effect of Pimecrolimus.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Pimecrolimus may enhance the immunosuppressive effect of Corticosteroids (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of Pimecrolimus.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May decrease the metabolism of Pimecrolimus.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): Pimecrolimus may enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): Pimecrolimus may enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the immunosuppressive effect of Pimecrolimus.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Pimecrolimus may enhance the immunosuppressive effect of Methotrexate. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F209924"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies following topical application.</p></div>
<div class="block brc drugH1Div" id="F5281671"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if pimecrolimus is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block pha drugH1Div" id="F209907"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Penetrates inflamed epidermis to inhibit T cell activation by blocking transcription of proinflammatory cytokine genes such as interleukin-2, interferon gamma (Th1-type), interleukin-4, and interleukin-10 (Th2-type). Pimecrolimus binds to the intracellular protein FKBP-12, inhibiting calcineurin, which blocks cytokine transcription and inhibits T-cell activation. Prevents release of inflammatory cytokines and mediators from mast cells <i>in vitro</i> after stimulation by antigen/IgE.</p></div>
<div class="block phk drugH1Div" id="F209921"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Time to significant improvement: 8 days (Wellington 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Topical: Low systemic absorption; blood concentration of pimecrolimus was routinely &lt;2 ng/mL with treatment of atopic dermatitis in adult patients (13% to 62% BSA involvement); blood concentration of pimecrolimus was &lt;3 ng/mL in 26 pediatric patients 2 to 14 years of age with atopic dermatitis (20% to 69% BSA involvement). Significant percutaneous absorption with systemic serum concentrations may occur in children due to the larger surface area to body mass ratio seen in pediatric patients (Segal 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99.5%, primarily to various lipoproteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via cytochrome (CYP) P450 3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: Oral: 30 to 40 hours (Wellington 2001)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Topical: 2 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (78.4% as metabolites; &lt;1% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F209925"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Elidel | Pmec</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Douglan | Elidel | Velov</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Elidel | Rizan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aregen | Elidel</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Elidel | Pacroma | Picon</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Douglan | Ducran | Elidel</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Camish | Elidel</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Elidel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.40">
<a name="USP.40"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31408687">
<a name="31408687"></a>Chang HC, Hsu YP, Huang YC. The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis. <i>J Am Acad Dermatol</i>. 2020;82(1):243-245. doi:10.1016/j.jaad.2019.07.108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/31408687/pubmed" id="31408687" target="_blank">31408687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34342763">
<a name="34342763"></a>da Silva EL, de Lima TB, Rados PV, Visioli F. Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis. <i>Clin Oral Investig</i>. 2021;25(9):5149-5169. doi:10.1007/s00784-021-04072-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/34342763/pubmed" id="34342763" target="_blank">34342763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11907497">
<a name="11907497"></a>Eichenfield LF, Lucky AW, Boguniewicz M, et al, “Safety and Efficacy of Pimecrolimus (ASM 981) Cream 1% in the Treatment of Mild and Moderate Atopic Dermatitis in Children and Adolescents,” <i>J Am Acad Dermatol</i>, 2002, 46(4):495-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/11907497/pubmed" id="11907497" target="_blank">11907497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elidel.1">
<a name="Elidel.1"></a>Elidel (pimecrolimus) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32738429">
<a name="32738429"></a>Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>J Am Acad Dermatol.</i> 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/32738429/pubmed" id="32738429" target="_blank">32738429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18608735">
<a name="18608735"></a>Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. <i>J Dermatolog Treat</i>. 2009;20(1):14-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/18608735/pubmed" id="18608735" target="_blank">18608735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14988682">
<a name="14988682"></a>Hanifin JM, Cooper KD, Ho VC, et al, “Guidelines of Care for Atopic DErmatitis, Developed in Accordance With the American Academy of Dermatology (AAD)/American Academy of Dermatology Association: Administrative Regulations for Evidence-Based Clinical Practice Guidelines," <i>J Am Acad Dermatol</i>, 2004, 50(3):391-404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/14988682/pubmed" id="14988682" target="_blank">14988682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15523351">
<a name="15523351"></a>Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. <i>J Am Acad Dermatol</i>. 2004;51(5):731-738.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/15523351/pubmed" id="15523351" target="_blank">15523351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18328059">
<a name="18328059"></a>Karabulut AA, Izol Serel B, Eksioglu HM. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. <i>J Eur Acad Dermatol Venereol</i>. 2008;22(6):729-734.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/18328059/pubmed" id="18328059" target="_blank">18328059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21954922">
<a name="21954922"></a>Kim MB, Kim GW, Park HJ, et al. Pimecrolimus 1% cream for the treatment of rosacea. <i>J Dermatol</i>. 2011;38(12):1135-1139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/21954922/pubmed" id="21954922" target="_blank">21954922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19594764">
<a name="19594764"></a>Koca R, Altinyazar HC, Ankarali H, Muhtar S, Tekin NS, Cinar S. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. <i>Clin Exp Dermatol</i>. 2010;35(3):251-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/19594764/pubmed" id="19594764" target="_blank">19594764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31141108">
<a name="31141108"></a>Lee JH, Kwon HS, Jung HM, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. <i>JAMA Dermatol</i>. 2019;155(8):929-938. doi:10.1001/jamadermatol.2019.0696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/31141108/pubmed" id="31141108" target="_blank">31141108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21175873">
<a name="21175873"></a>McCaughey C, Machan M, Bennett R, Zone JJ, Hull CM. Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety. <i>J Eur</i>
<i>Acad Dermatol Venereol</i>. 2011;25(9):1061-1067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/21175873/pubmed" id="21175873" target="_blank">21175873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17438179">
<a name="17438179"></a>Passeron T, Lacour JP, Fontas E, Ortonne JP. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. <i>Arch Dermatol</i>. 2007;143(4):472-476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/17438179/pubmed" id="17438179" target="_blank">17438179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23837743">
<a name="23837743"></a>Segal AO, Ellis AK, Kim HL. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. <i>Allergy Asthma Clin Immunol</i>. 2013;9(1):24. doi:10.1186/1710-1492-9-24<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/23837743/pubmed" id="23837743" target="_blank">23837743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19651562">
<a name="19651562"></a>Stinco G, Piccirillo F, Forcione M, Valent F, Patrone P. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. <i>Eur J Dermatol</i>. 2009;19(6):588-593.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/19651562/pubmed" id="19651562" target="_blank">19651562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15857105">
<a name="15857105"></a>Swift JC, Rees TD, Plemons JM, Hallmon WW, Wright JC. The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. <i>J Periodontol</i>. 2005;76(4):627-635. doi:10.1902/jop.2005.76.4.627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/15857105/pubmed" id="15857105" target="_blank">15857105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22860621">
<a name="22860621"></a>Taieb A, Alomar A, Böhm M, et al; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. <i>Br J Dermatol</i>. 2013;168(1):5-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/22860621/pubmed" id="22860621" target="_blank">22860621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed April 4, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18647310">
<a name="18647310"></a>Volz T, Caroli U, Lüdtke H, et al. Pimecrolimus cream 1% in erosive oral lichen planus--a prospective randomized double-blind vehicle-controlled study. <i>Br J Dermatol</i>. 2008;159(4):936-941.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/18647310/pubmed" id="18647310" target="_blank">18647310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12093983">
<a name="12093983"></a>Wahn U, Bos JD, Goodfield M, et al, “Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children,” <i>Pediatrics</i>, 2002, 110(1 Pt 1):e2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/12093983/pubmed" id="12093983" target="_blank">12093983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17493072">
<a name="17493072"></a>Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. <i>Br J Dermatol</i>. 2007;156(4):728-732.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/17493072/pubmed" id="17493072" target="_blank">17493072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11929333">
<a name="11929333"></a>Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. <i>Drugs.</i> 2002;62(5):817-840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimecrolimus-drug-information/abstract-text/11929333/pubmed" id="11929333" target="_blank">11929333</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10162 Version 187.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
